Suspension of trading

Spexis AG Share Price Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Delayed Swiss Exchange 16:36:37 19/03/2025 GMT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 30/03/2022
Director of Finance/CFO - 31/07/2024
Director TitleAgeSince
Chairman 70 19/11/2019
Director/Board Member 65 31/05/2013
Director/Board Member 80 29/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
+1.70%-0.74%+18.48%-10.41% 67.88B
-1.02%-0.16%+36.15%+205.44% 53.23B
+1.78%+54.50%+54.50%+54.50% 48.71B
+2.69%-1.53%-55.83%-55.20% 38.98B
-1.01%+0.10%+52.17%-23.84% 29.55B
+1.02%+2.78%+69.33%+89.65% 23.75B
+2.89%-6.49%+62.90%-53.06% 22.07B
+0.62%-2.44%-4.26%+145.63% 19.84B
-0.04%+0.22%+65.37%+126.21% 16.57B
Average +0.75%+0.16%+20.99%+37.97% 35.62B
Weighted average by Cap. +0.88%+0.97%+28.80%+49.80%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B